Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 943-944

  Lat, Asma ^a,b,e   Thompson III, George R ^a,b,f   Rinaldi, Michael G ^c   Dorsey, Sheryl A ^c   Pennick, Gennethel ^c   Lewis II, James S ^b,d  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Health Science Center   (United States)

^d UNIVERSITY HEALTH SYSTEM   (United States)

^e Department of Medicine   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CIPROFLOXACIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIMICROBIAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOPSY; BRAIN TISSUE; CANDIDA ALBICANS; CANDIDA GLABRATA; CASE REPORT; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; CYST FLUID; DECORTICATION; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGUS ACHALASIA; ESOPHAGUS RUPTURE; FUNGUS CULTURE; FUNGUS GROWTH; HEMIPARESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; INVASIVE CANDIDIASIS; LIVER FUNCTION TEST; MALE; MINIMUM INHIBITORY CONCENTRATION; PANCREAS PSEUDOCYST; PNEUMOMEDIASTINUM; PNEUMOTHORAX; PRIORITY JOURNAL; THORACOTOMY;

ADULT; AGED; ANTIFUNGAL AGENTS; BRAIN; CANDIDIASIS; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MALE; PANCREATIC PSEUDOCYST;

EID: 75749106998     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01294-09     Document Type: Article

References (13)

1. Banks, P. A., and M. L. Freeman. 2006. Practice guidelines in acute pancreatitis. Am. J. Gastroenterol. 101:2379-2400.
2. Chandrasekar, P. H., and J. D. Sobel. 2006. Micafungin: a new echinocandin. Clin. Infect. Dis. 42:1171-1178.
3. De Waele, J. J., D. Vogelaers, S. Blot, and F. Colardyn. 2003. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin. Infect. Dis. 37:208-213.
4. Groll, A. H., D. Mickiene, V. Petraitis, R. Petraitiene, K. H. Ibrahim, S. C. Piscitelli, I. Bekersky, and T. J. Walsh. 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. 45:3322-3327.
5. Hebert, M. F., H. E. Smith, T. C. Marbury, S. K. Swan, W. B. Smith, R. W. Townsend, D. Buell, J. Keirns, and I. Bekersky. 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45:1145-1152.
6. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised doubleblind trial. Lancet 369:1519-1527.
7. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
8. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. de Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, B. R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
9. Petraitis, V., R. Petraitiene, A. H. Groll, K. Roussillon, M. Hemmings, C. A. Lyman, T. Sein, J. Bacher, I. Bekersky, and T. J. Walsh. 2002. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46:1857-1869.
10. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
11. Seibel, N. L., C. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J. Keirns, W. Lau, D. Facklam, D. Buell, and T. J. Walsh. 2005. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49:3317-3324.
12. Solomkin, J. S., J. E. Mazuski, E. J. Baron, R. G. Sawyer, A. B. Nathens, J. T. DiPiro, T. Buchman, E. P. Dellinger, J. Jernigan, S. Gorbach, A. W. Chow, and J. Bartlett. 2003. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 37:997-1005.
13. Whitcomb, D. C. 2006. Clinical practice. Acute pancreatitis. N. Engl. J. Med. 18:2142-2150.